JP Morgan Chase
RPRX icon

JP Morgan Chase’s Royalty Pharma RPRX Stock Holding History

JP Morgan Chase’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$325K Buy
+7,000
New +$307K ﹤0.01% 5240
2022
Q2 		– Sell
-700
Closed -$27K – 6819
2022
Q1 		$27K Buy
+700
New +$27.5K ﹤0.01% 6006
2021
Q4 		– Sell
-25,200
Closed -$911K – 6917
2021
Q3 		$911K Buy
+25,200
New +$979K ﹤0.01% 4384

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

JP Morgan Chase's RPRX Position: Q1 2026 in Review

JP Morgan Chase increased its Royalty Pharma (RPRX) stake by 11% in Q1 2026, buying an estimated $7.05M and bringing the position to 1,679,671 shares worth $77.9M. The position accounts for 0.01% of the portfolio, ranked #1117.

JP Morgan Chase first reported a position in RPRX in Q2 2020 and has held it in 24 quarters since. The position peaked at $335M in Q3 2022. 588 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

  • JP Morgan Chase held 1,679,671 shares of Royalty Pharma worth $77.9M as of Q1 2026.
  • JP Morgan Chase bought 161,061 Royalty Pharma shares in Q1 2026, an estimated $7.05M.
  • Royalty Pharma made up 0.01% of JP Morgan Chase's portfolio in Q1 2026, its #1117 holding.
  • JP Morgan Chase first reported a position in Royalty Pharma in Q2 2020 and has held it in 24 quarters since.
  • JP Morgan Chase's Royalty Pharma position peaked at $335M in Q3 2022.
  • 588 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.